Benitec Biopharma (NASDAQ: BNTC) — Perfil da empresa, notícias e dados financeiros
Benitec Biopharma specializes in gene-silencing technology for chronic diseases, addressing unmet medical needs through innovative therapies.
Benitec Biopharma
Benitec Biopharma (NASDAQ:BNTC) is a dynamic biotechnology firm focused on the development of genetic medicines. Benitec's innovative approach leverages its proprietary gene-silencing technology, called DNA-directed RNA interference (ddRNAi), to create therapies aimed at treating chronic and life-threatening diseases. The company's pipeline includes projects targeting conditions such as hepatitis B, age-related macular degeneration, and oculopharyngeal muscular dystrophy, showcasing its commitment to addressing unmet medical needs through groundbreaking research. With a mission to pioneer the next generation of genetic medicines, Benitec strives to improve patient outcomes and alter the course of disease with its cutting-edge technologies and therapies.
Resumo
Operações
Produtos e/ou serviços de Benitec Biopharma
- BB-301 for oculopharyngeal muscular dystrophy, a gene-silencing therapy aiming to reduce the production of toxic proteins causing muscle weakness.
- Gene therapy projects targeting chronic and life-threatening conditions, leveraging DNA-directed RNA interference technology.
- BB-103 for hepatitis B, a treatment designed to disrupt the viral replication process.
- Collaborations with academic and biomedical entities to develop innovative gene therapies for various diseases.
- Research on ddRNAi technology, a proprietary platform for developing treatments targeting genetic disorders.
- Development services for third-party gene therapy products, including custom gene-silencing constructs and licensing of proprietary technologies.
equipe executiva do Benitec Biopharma
- Jerel A. BanksExecutive Chairman & CEO
- Megan Joan BostonCFO & Secretary
- Sophie MukadamChief Operating Officer
- Michael GrahamHead of Discovery & Founding Scientist
- Claudia KlothSenior Vice President of Manufacturing
Histórico de dividendos
Dividendos por ação pagos pela Benitec Biopharma , por ano fiscal.
| Ano fiscal | Intermediário | Final | Especial | Total |
|---|---|---|---|---|
| FY2018 | — | — | — | $0.7650 |
Principais indicadores financeiros
Resultados divulgados pela Benitec Biopharma , em USD.
- Cap. de mercado
- 307 mi
- Receita (TTM)
- 7 mil
- P/L
- —
- LPA (diluído, TTM)
- -1.0
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 0 | -51,2 mi | -45,5 mi | |
| 0 | -41,8 mi | -37,9 mi | |
| 216 mil | -22,5 mi | -21,8 mi | |
| 75 mil | -19,1 mi | -19,6 mi |